Navigation Links
Cepheid Reports 2012 First Quarter Results
Date:4/19/2012

events, they are subject to various risks and uncertainties, and actual results could differ materially from the Company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: our success in increasing direct sales and the effectiveness of our sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop new products and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites, including for Healthcare Associated Infections (HAIs); the Company's ability to successfully introduce and sell products in clinical markets other than HAIs; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; variability in systems placements and reagent pull-through in the Company's HBDC program; unforeseen supply, development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the Company's reliance on distributors in some regions to market, sell and support its products; the occurrence of unforeseen expenditures, acquisitions or other transactions; costs associated with litigation; the impact of competitive products and pricing; the Company's ability to manage geographically-dispersed operations; and underlying market conditions worldwide.  Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K, its most recent Quarterly Report on Form 10-Q, and its other reports filed with the Securities and Exchange Commission.

All forward-looking statements and reasons why results might differ included in this release are made a
'/>"/>

SOURCE Cepheid
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Cepheid Schedules 2011 Third Quarter Financial Results Announcement and Webcast
2. Cepheid Announces Release of Updated Xpert BCR-ABL Monitor Test
3. Cepheid to Webcast Upcoming Financial Presentations
4. Cepheid Schedules 2011 Second Quarter Financial Results Announcement and Webcast
5. Cepheid CEO John Bishop Named Ernst & Young Entrepreneur Of The Year® 2011 Northern California Award winner
6. Cepheid Appoints Vice President of Infectious Disease Research & Development
7. LABSCO to Distribute Cepheid GeneXpert® Systems and Tests
8. Cepheid Appoints LABSCO as US Small Hospital Distributor
9. Cepheid Reports 2011 First Quarter Results
10. Cepheid Extends Rapid Molecular Diagnostics Leadership with FDA Clearance of Xpert Clostridium difficile/Epi
11. Cepheid Announces Nomination of Geisinger Health System CEO and Renowned Oncology Researcher to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Massachusetts General ... AMGN ) announced today that they ... and validate new therapeutic targets and develop novel ... disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide ... from the Journal of Drugs in Dermatology ... Conference (ODAC). The event is January 17-20, 2014, at the Omni ... . The ODAC is a distinguished ...
(Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
... WA – June 25 – MediQuest Therapeutics,Inc., ... for inflammatory and infectious diseases, today announced,the ... of Vascana,– a topical formulation designed to ... primary end point and demonstrated statistical,significance, with ...
... Company updates progress and upcoming,milestones on its ... /PRNewswire-FirstCall/ - SemBioSys,Genetics Inc. , a biotechnology ... metabolic and cardiovascular disease,today announced positive preclinical ... insulin. The Company,presented its findings at the ...
Cached Medicine Technology:MediQuest Concludes Confirmatory Phase III Study of Raynaud’s,Therapy 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 2SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 3SemBioSys Presents Positive Insulin Data at the American Diabetes,Association Conference 4
(Date:4/23/2014)... Inverse Effects of Midlife Occupational and Leisure Time Physical ... occupational physical activity in midlife increases the risk of ... decreases the risk. This is found in a study ... years. The study was conducted at the Gerontology Research ... Health. , Heavy physical labor is often repetitive, wears ...
(Date:4/23/2014)... depletion of self-control, according to research published in ... Psychological Science. , Self-control can be difficult sticking ... a boring textbook are hard things to do. Considerable ... self-control for a long period seems to "deplete" our ... "It is as if self-control is a limited resource ...
(Date:4/23/2014)... of Alzheimer,s disease has been a rapidly evolving ... the latest crook in the research road, scientists ... between proteins associated with the disease. The report, ... Neuroscience , could have important implications for developing ... and colleagues explain that for years, research has ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
(Date:4/22/2014)... researchers have characterized a set of clock genes that ... types of species, from flies to humans. Over 15 ... there are more. A team from the Perelman School ... big-data approaches could find them. , To accelerate ... professor of Pharmacology and first author Ron Anafi, MD, ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... networks in fruit flies has led researchers to a sensitive ... most common type of kidney cancer. In the journal ... at the University of Chicago shows that the biomarker known ... renal cell carcinomas but not by normal kidney tissue. , ...
... new 30" in groundbreaking new calendarHAGATNA, Guam, Jan. 27 ... natural calendar to promote her "Look Good Naked" theme ... is beautifully captured au natural and semi-nude in high-quality ... in her beautiful cottage home. "I wanted to show ...
... HCA Healthcare announces the following Webcast:, What: ... 10:00 EST, Where: http://www.videonewswire.com/event.asp?id=55052 , How: ... web at the, ... +1-615 344 ...
... Jan. 27 /PRNewswire-FirstCall/ - QLT Inc. ("QLT") (NASDAQ: ... modified "Dutch Auction" tender offer (the "Offer"), which expired at ... on the preliminary report of the depository for the Offer, ... shares (the "Shares") at a price of US$2.50 per Share, ...
... -- The University of Texas at San Antonio (UTSA) ... College of Engineering has been awarded a $199,884, 24-month ... energy combustion. , "This is one of the first ... combustion, gasification and energy efficiency," said Efstathios Michaelides, mechanical ...
... adds affordable, professionally refurbished Hill-Rom hospital beds to its ... ... -- DRE Medical Equipment — named by Business First of Louisville ... refurbished Hill-Rom hospital beds . DRE’s extensive lineup of economically-priced ...
Cached Medicine News:Health News:Roadkill study could speed detection of kidney cancer 2Health News:QLT announces preliminary results of tender offer 2Health News:QLT announces preliminary results of tender offer 3Health News:UTSA receives federal funding for fossil fuel research 2Health News:DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds 2Health News:DRE Medical Equipment Now Sells Reconditioned Hill-Rom Hospital Beds 3
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: